Overexpression of MDM2 and CDK4 occurs in several tumour types such as liposarcoma, melanoma and osteosarcomas, and targeting both MDM2 and CDK4 is of interest in such settings, evidenced by a synergistic effect in liposarcomas [117]. Here, MDM2 is linked to melanoma.